Membrane Target Detection for Leukemia Treatment
Tumor Cell and DNA Detection in the Peripheral Blood of Patients With Hematological Malignancy
University of Missouri-Columbia
50 participants
Mar 20, 2020
OBSERVATIONAL
Conditions
Summary
Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. We also found DPP4 is highly expressed in other hematological malignancies in our mouse model, thus we would like to use human samples to investigate the role of DPP4 in hematological malignancy development and the mechanism underlying, especially to deeply understand the role of DDP4 in leukemia.
Eligibility
Inclusion Criteria2
- All hematological malignancy patients.
- Must be 18 years old.
Exclusion Criteria6
- Participants with impaired decision-making capacities;
- Pregnant women or fetuses;
- Children (under 18 in Missouri, also dependent on State law);
- Non-viable neonates or neonates of uncertain viability (neonates=newborns);
- Non-English-speaking subjects;
- Prisoners.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04841447